作为HR+/HER2-乳腺癌细胞治疗点的CDK4/6 - - 当前治疗状态
Kamila Krupa1, Anna Liszcz-Tymoszuk1, Natalia Czerw1
1Students' Scientific Organization of Cancer Cell Biology, Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland.
Cancers
|March 28, 2025
概括
像palbociclib,ribociclib和abemaciclib这样的CDK4/6抑制剂改善了HR+/HER2-乳腺癌治疗. 本综述详细介绍了dalpiciclib.lib的有效性,安全性和潜在用途.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌是全球领先的瘤,有各种各样的亚型.
- 激素受体 (HR) 和HER2表达影响治疗策略.
- 循环素依赖性激酶4和6 (CDK4/6) 抑制剂代表了HR+/HER2-乳腺癌治疗的重大进展.
研究的目的:
- 总结CDK4/6抑制剂 (palbociclib,ribociclib,abemaciclib) 对HR+/HER2-乳腺癌的临床疗效和安全性.
- 为了比较已批准的CDK4/6抑制剂的有效性,剂量和不良影响.
- 讨论dalpiciclib在乳腺癌治疗中的潜在作用.
主要方法:
- 临床试验的审查 (例如,PALOMA,MONALEESA,MONARCH,MONARCHE,NATALEE). 临床试验的审查是指临床试验的临床试验,这些临床试验的临床试验是指临床试验的临床试验.
- 对药物的疗效,安全性概况和治疗建议的数据的分析.
- 对palbociclib,ribociclib和abemaciclib进行比较评估.
主要成果:
- 帕尔博西基利布,里博西基利布和阿贝马西基利布是HR+/HER2-乳腺癌的已知治疗方法,用于组合或单一治疗.
- 临床试验已经阐明了它们的有效性,剂量和副作用概况的差异.
- 目前正在进行的研究,包括辅助疗法研究,继续改进它们的应用.
结论:
- CDK4/6抑制剂已经改变了HR+/HER2-乳腺癌的管理.
- 了解个体药物特征对于最佳的患者护理至关重要.
- 达尔皮西克利布对未来的乳腺癌治疗选择有希望.
相关概念视频
Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...


